Liminatus Pharma, Inc. — Form 8-K
Filed July 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 68/100
What the filing says
Liminatus Pharma agreed to acquire InnocsAI LLC, a CAR-T therapy technology company, by issuing 1,600,000,000 common shares at $0.20/share (nominal $320M equity value) plus contingent value rights representing 20% of net proceeds from future strategic exits. Shares capped at 19.99% of Liminatus' pre-transaction outstanding; excess consideration paid in convertible preferred stock (160,000 shares, 10,000:1 conversion ratio) requiring stockholder approval. Closing targeted December 31, 2026, contingent on regulatory approvals and Nasdaq listing maintenance.
Why this rating
Transformational M&A at ~145% of Liminatus' $221M market cap; major equity dilution (19.99% common cap + convertible shares) and execution risk on CAR-T platform justify 'significant' score. However, neutral impact reflects mixed risk-reward: high dilution and contingent consideration offset by potentially valuable IP, though deal completion and value realization remain uncertain.
See more from July 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.